Acutaas Chemicals Investor Presentation on Q2 & H1 FY26 Results
Acutaas Chemicals releases investor presentation on Q2 & H1 FY26 results, reporting revenue of ₹3,062 million (₹306.2 crore), EBITDA of ₹953 million (₹95.3 crore) and PAT of ₹719 million (₹71.9 crore).
The results show substantial growth and profitability, which is likely to have a moderate positive impact on investor sentiment and the company's stock performance.
The announcement highlights positive financial results for Q2 FY26, including significant YoY growth in revenue, EBITDA, and PAT. The management's confidence in delivering around 25% revenue growth for the full year further supports a positive outlook.
* Acutaas Chemicals Limited has released an investor presentation on financial results for the second quarter and half year ended on 30 September 2025. * Revenue for Q2 FY26 grew by 24.1% year-on-year to ₹3,062 million (₹306.2 crore). * EBIDTA for Q2 FY26 stood at ₹953 million (₹95.3 crore), a YoY increase of 94.8%. * PAT for Q2 FY26 was ₹719 million (₹71.9 crore), up by 91.3% YoY. * Management Commentary: Mr. Naresh Patel, Executive Chairman and Managing Director, mentioned that the company's focus on building a long-term, sustainable business is yielding tangible results as they strengthen global partnerships and expand into new growth verticals such as Battery Chemicals and Semiconductors. They remain confident of delivering around 25% revenue growth for the full year. * Q2 FY26 Revenue from Operations: Advanced Intermediates: ₹2,626 million (₹262.6 crore), Specialty Chemicals: ₹436 million (₹43.6 crore). * Q2 FY26 EBITDA: ₹953 million (₹95.3 crore) with a margin of 31.1%. * Q2 FY26 PAT: ₹719 million (₹71.9 crore) with a margin of 23.5%.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.